Prudential Financial Inc. Increases Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Prudential Financial Inc. raised its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 8.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 41,193 shares of the company’s stock after buying an additional 3,254 shares during the period. Prudential Financial Inc.’s holdings in Krystal Biotech were worth $6,815,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of KRYS. Wilmington Savings Fund Society FSB purchased a new position in Krystal Biotech in the third quarter valued at $40,000. Avanza Fonder AB acquired a new stake in Krystal Biotech in the 4th quarter valued at about $119,000. KBC Group NV boosted its stake in shares of Krystal Biotech by 46.3% in the 4th quarter. KBC Group NV now owns 939 shares of the company’s stock valued at $147,000 after buying an additional 297 shares during the period. Blue Trust Inc. grew its position in shares of Krystal Biotech by 74.4% during the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock worth $159,000 after buying an additional 433 shares in the last quarter. Finally, US Bancorp DE increased its stake in shares of Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company’s stock worth $161,000 after buying an additional 82 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. Chardan Capital boosted their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. HC Wainwright restated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Friday, February 28th. Jefferies Financial Group assumed coverage on Krystal Biotech in a report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price target for the company. Finally, Citigroup increased their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a report on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $220.00.

Krystal Biotech Price Performance

NASDAQ KRYS opened at $183.92 on Monday. The company has a fifty day moving average of $170.82 and a two-hundred day moving average of $173.55. The company has a market capitalization of $5.30 billion, a PE ratio of 61.51 and a beta of 0.87. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same quarter last year, the business posted $0.30 EPS. The firm’s quarterly revenue was up 116.4% compared to the same quarter last year. On average, research analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).